NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT03499795 2023-07-14VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2Inovio PharmaceuticalsPhase 2 Completed23 enrolled 19 charts
NCT02399813 2023-03-20A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal CanalAdvaxis, Inc.Phase 2 Completed36 enrolled 11 charts
NCT05694728 2023-01-23A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineBeijing Health Guard Biotechnology, IncPhase 2 Completed780 enrolled
NCT01807546 2017-06-26Oral Rigosertib for Squamous Cell CarcinomaTraws Pharma, Inc.Phase 2 Completed64 enrolled